Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications - A...

Dexmedetomidine (DEX), a highly selective α2-adrenoceptor agonist, may produce arousable sedation through locus coeruleus-mediated noradrenergic suppression while preserving respiratory drive. Its clinical applications have expanded beyond intensive care unit (ICU) sedation to procedural sedation, anesthesia adjunction, and non-operating room settings. However, substantial heterogeneity in dosing regimens has impeded the formulation of standardized clinical protocols.

This narrative review synthesizes evidence identified through a MeSH-based search of PubMed, Embase, and the Cochrane Library (January 2020-Dec 2025), supplemented by chain referencing of foundational earlier studies, to evaluate dexmedetomidine dosing strategies, pharmacokinetics, safety, comparative efficacy, combination regimens, non-intravenous routes, and special-population considerations across sedation and anesthesia contexts.

Reported bolus doses span a 60-fold range (0.05-3 μg/kg). In adults, doses of 0.25-0.5 μg/kg over 10 minutes appear to provide adequate procedural sedation with acceptable hemodynamic effects; pediatric studies report success rates exceeding 90% at 2 μg/kg. Dose-dependent bradycardia and hypotension are common but generally transient. Compared with propofol, DEX has been associated with more favorable respiratory stability but slower onset and recovery. Compared with conventional sedatives (primarily midazolam), DEX has been associated with lower delirium incidence and shorter mechanical ventilation duration in selected ICU trials, although these findings derive from heterogeneous study designs. Individual trials have reported opioid-sparing effects of up to 60%, though generalizability requires confirmation. Combination regimens with ketamine or propofol may offer synergistic benefits. Intranasal and subcutaneous routes provide non-invasive alternatives, particularly in pediatric practice. Special populations-including neonates, patients with cardiorespiratory morbidities, and obese patients-require population-specific dosing adjustments.

The available evidence suggests that dexmedetomidine offers a generally favorable safety profile across sedation and anesthesia contexts. However, conclusions are limited by dosing heterogeneity, small sample sizes, inconsistent outcome definitions, and absent long-term safety data. Standardized multicenter trials with uniform outcome criteria are needed to establish definitive dosing recommendations.